title: Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine.
abstract: Effective vaccines against genital herpes simplex virus type 2 (HSV-2) may need to induce genital tract immune responses. To determine local antibody responses to HSV-2 glycoproteins gB2 and gD2 in an intramuscular subunit vaccine, cervical secretions from HSV-seronegative women and HSV-1-seropositive women were tested for IgG and IgA to gB2 and gD2 by enhanced chemiluminescence Western blot. Most (94%) of the seronegative subjects developed cervical IgG to gB2, IgG to gD2, and IgA to gB2; 72% developed IgA to gD2. All HSV-1-seropositive subjects had cervical IgG responses to vaccine gB2 and gD2, 85% had IgA responses to gB2, and 50% had IgA responses to gD2. Responses were more rapid and titers more consistently sustained in the HSV-1-seropositive women. Further, vaccination resulted in cervical IgG and IgA titers comparable to those to HSV-2 gB2 and gD2 in response to recurrent HSV-2 genital infection.
authors.affiliation: University of Washington and The Mountain-Whisper-Light Statistical Consulting, Seattle 98105, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Ashley
authors.forename: F M
authors.initials: FM
authors.lastname: Crisostomo
authors.forename: M
authors.initials: M
authors.lastname: Doss
authors.forename: R E
authors.initials: RE
authors.lastname: Sekulovich
authors.forename: R L
authors.initials: RL
authors.lastname: Burke
authors.forename: M
authors.initials: M
authors.lastname: Shaughnessy
authors.forename: L
authors.initials: L
authors.lastname: Corey
authors.forename: N L
authors.initials: NL
authors.lastname: Polissar
authors.forename: A G
authors.initials: AG
authors.lastname: Langenberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis* / Q000097:blood; D002584:Cervix Uteri / Q000276:immunology*; D005260:Female; D006558:Herpes Genitalis / Q000517:prevention & control*; D006561:Herpes Simplex / Q000276:immunology*; D018259:Herpesvirus 1, Human / Q000276:immunology; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis / Q000097:blood; D008875:Middle Aged; D014614:Vaccines, Synthetic / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C044525:glycoprotein B, herpes simplex virus type 2; C040570:glycoprotein D-herpes simplex virus type 2